Efinopegdutide is being developed by Merck Sharp & Dohme LLC for the treatment of compensated cirrhosis secondary to MASH, a condition with significant unmet medical need and increasing prevalence due to rising obesity and diabetes rates. The global market for therapies targeting liver diseases, particularly NASH/MASH, is projected to grow substantially, with numerous competitors also in development. Successful outcomes from this trial could position Merck favorably in a competitive landscape, potentially leading to a first-in-class designation if efinopegdutide demonstrates superior efficacy and safety. Diligence should focus on the regulatory pathway, potential market access challenges, and the evolving competitive landscape as other candidates progress through clinical trials.